文献速递骨质疏松与钙磷/甲状旁腺

唑来膦酸改善糖皮质激素依赖性杜氏肌营养不良男孩骨密度:随机对照试验

Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

结果显示唑来膦酸组腰椎骨密度Z值较基线变化显著高于对照组,但小样本未能证明骨折获益。

要点

  • 唑来膦酸可显著提高糖皮质激素依赖性DMD男孩腰椎骨密度。
  • 对照组出现5例Genant 3级椎体骨折,唑来膦酸组为0例。
  • 两组在活动能力、疼痛和骨转换标志物方面无显著差异。

核心结论

  • 唑来膦酸改善糖皮质激素依赖性DMD男孩的骨密度,虽小样本未能证明骨折获益,但骨密度改善可能减少椎体骨折发生。

主要发现

  • 12个月时腰椎骨密度Z值较基线变化的组间平均差异为1.2 SD(95%CI 0.9-1.5),唑来膦酸组高19.3%(14.6-24.0)。
  • 对照组5例发生Genant 3级椎体骨折,唑来膦酸组0例。
  • 12个月时唑来膦酸组桡骨和胫骨pQCT的骨小梁骨矿物质含量和体积骨密度高于对照组;24个月时桡骨差异仍存在,胫骨差异不再显著。
  • 两组在12和24个月时的活动能力、疼痛和骨转换标志物相似。

关键数值与推荐

  • 唑来膦酸输注方案:第0、3个月0.025 mg/kg,第6、12、18个月0.05 mg/kg,共5次,联合钙和维生素D。

临床怎么用

  • 对于糖皮质激素依赖性DMD男孩,可考虑使用唑来膦酸以改善骨密度,但需注意小样本未能证实骨折获益。

局限性

  • 样本量小,无法证明骨折获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with glucocorticoid-dependent Duchenne muscular dystrophy (DMD) have increased fracture risk and reduced bone mineral density (BMD), often precipitating mobility loss. OBJECTIVE: To investigate use of zoledronic acid (ZA) in DMD in improving BMD. METHODS: Two arm, parallel, randomized controlled trial, set in pediatric hospitals across Australia and New Zealand. Sixty-two (31 per arm) boys with glucocorticoid-dependent DMD between 6 and 16 years were included. Five ZA infusions (0.025 mg/kg at months 0, and 3, and 0.05 mg/kg at months 6, 12, and 18), plus calcium and vitamin D, were compared with calcium and vitamin D alone. The main outcome measures were change in lumbar spine (LS) BMD raw and Z-score by dual energy absorptiometry x-ray (DXA) at 12 and 24 months, secondary outcomes assessing mobility, fracture incidence, bone turnover, peripheral quantitative computerized (pQCT) and pain scores. RESULTS: At 12 and 24 months, mean difference in changes of LS BMD Z-score from baseline was 1.2 SD (95% CI 0.9-1.5), higher by 19.3% (14.6-24.0) and 1.4 SD (0.9-1.9), higher by 26.0% (17.4-34.5) in ZA than control arms respectively (both P < .001). Five controls developed Genant 3 vertebral fractures, 0 in the ZA arm. Mobility, pain, and bone turnover markers were similar between arms at 12 and 24 months. Trabecular BMC and vBMD pQCT at radius and tibia were greater at 12 months in the ZA cohort than control; the evidence for this difference remained at 24 months for radius but not tibia. CONCLUSION: ZA improved BMD in glucocorticoid-dependent DMD boys. Although the small cohort precluded demonstrable fracture benefit, improved BMD might reduce incident vertebral fracture.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zacharin M, Lim A, Gryllakis J, et al. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy. J Clin Endocrinol Metab. 2021. PMID: 33954789. doi:10.1210/clinem/dgab302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。